Physician profile
Adolfo E Kaplan
NPI 1417984899
$9,452.56
in general payments reported to CMS, 2019-2025
23 companies · $892 in 2025
The $892 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,461 · 2020: $115 · 2021: $296 · 2022: $5,141 · 2023: $384 · 2024: $163 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,103 · Education: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,102.90 |
| Education | $335.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $5,001.45 | 2019-2025 | Tyvaso |
| Pulmonx Corporation | $1,377.27 | 2019-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Olympus Corporation of The Americas | $868.65 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $453.00 | 2019-2023 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $277.96 | 2024-2025 | Winrevair |
| Medtronic, INC. | $174.13 | 2022-2025 | Illumisite |
| Boston Scientific Corporation | $161.41 | 2021-2022 | |
| Insmed, INC. | $148.18 | 2020-2025 | Arikayce |
| Eisai INC. | $125.00 | 2019 | |
| Genzyme Corporation | $124.99 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $108.48 | 2021 | |
| Galvanize Therapeutics, INC | $91.06 | 2025 | Aliya System |
| Philips North America LLC | $90.80 | 2025 | Respiratory |
| Avadel Cns Pharmaceuticals, LLC | $76.60 | 2024 | Lumryz |
| Fisher & Paykel Healthcare INC | $71.35 | 2025 | Fisher & Paykel Healthcare |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pinnacle Biologics, INC | $61.41 | 2025 | Photofrin |
| Advanced Respiratory, INC | $46.91 | 2021 | |
| Amgen INC. | $46.82 | 2022 | |
| Abiomed | $41.20 | 2025 | |
| Electromed, INC. | $36.68 | 2024-2025 | Smartvest |
| Grifols USA, LLC | $26.35 | 2025 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $22.72 | 2022 | |
| Gilead Sciences, INC. | $20.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adolfo Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.